• Exploring physicians’ perceptions of adherence levels, reasons for non-adherence, and opinions of how to improve adherence in leukaemia patients receiving treatment
  • Patient satisfaction in chemotherapy for leukaemia

Acute lymphoblastic leukaemia

  • Support in IRB submissions and scientific dissemination in acute lymphoblastic leukaemia
  • Burden of refractory acute lymphoblastic leukaemia on patients and caregivers

Acute myeloid leukaemia (AML)

  • Global value dossier and e-v@luate platform for a treatment in AML
  • Global value dossier, conference poster and medical writing support in AML
  • Quality of life analysis in the treatment of AML
  • Payer evidence council value communication materials (booklet, slides and Q&A) to inform phase III trial design in AML
  • Cost-effectiveness analysis and budget impact analysis for a prognostic and minimal residual genetic tests for AML
  • Systematic literature review of healthcare resource utilisation in AML
  • Literature review of resource utilisation in AML
  • Strategic consulting on AML
  • Health-related quality of life in elderly patients with AML: Position paper on an AML treatment for inclusion in a value dossier
  • Qualitative research to understand the value of extended overall survival to AML patients

Chronic lymphocytic leukaemia (CLL)

  • Utility study in advanced CLL
  • Abstract and manuscript on utility study results in CLL
  • Payer evidence dossiers for treatments of CLL
  • Mixed treatment comparison and training meeting on a global value dossier for a treatment for CLL
  • Health state preference study mapping the change over the course of the CLL disease process
  • Conference poster on the health state preference study mapping the change over the course of the CLL disease process
  • Global value dossier for a treatment in CLL
  • Statistical analysis plans and provision of PRO support to the client for their trials of a biological therapy cancer treatment for CLL
  • General consultancy agreement to review PRO measures in CLL
  • Analysis of PRO data from the CLL registry
  • Manuscript on a budget impact model for a cross-indication biosimilar in CLL

Chronic myeloid leukaemia (CML)

  • Value dossier support in CML linking myelosuppression with quality of life impact
  • Value dossier support in CML linking response to utilities and additional analysis
  • Critical review of PRO instruments in CML
  • Adverse event to PRO linking in CML
  • Manuscript on AE-PRO linking in CML
  • Targeted literature review and manuscript on factors associated with adherence in CML
  • Development of a link between side effects and PROs in CML – a univariate approach

Related categories

Experience,  Oncology,  Therapeutic area